ITEMS IN AFP WITH KEYWORD:
Aug 1, 2018 Issue
The Role of Proton Pump Inhibitor Therapy in Patients with Functional Dyspepsia [Cochrane for Clinicians]
There is moderate-quality evidence that PPIs are more effective than placebo at relieving overall symptoms in patients with functional dyspepsia (number needed to treat [NNT] = 11). Low-quality evidence suggests a small benefit of PPI therapy compared with prokinetics, and little to no benefit of PPI therapy vs. histamine H2 antagonists.
Dyspepsia affects up to 40 percent of adults each year and is often diagnosed as functional (nonulcer) dyspepsia. The defining symptoms are postprandial fullness, early satiation, or epigastric pain or burning in the absence of causative structural disease. These symptoms may coexist with symptoms o...
The American Gastroenterological Association (AGA) has released a position statement to reflect new evidence on the evaluation of dyspepsia. The AGA defines dyspepsia as chronic or recurrent pain or discomfort in the upper abdomen.
Sep 15, 2003 Issue
Evaluation of Epigastric Discomfort and Management of Dyspepsia and GERD [Practice Guidelines]
The Institute for Clinical Systems Improvement (ICSI) recently published a guideline on the evaluation and management of dyspepsia and gastroesophageal reflux disease (GERD).
Nov 1, 2001 Issue
Symptomatic Treatment and H. pylori Eradication Therapy for Nonulcer Dyspepsia [Cochrane for Clinicians]
Bismuth subcitrate, histamine H2-receptor antagonists or proton pump inhibitors could be recommended for short-term relief of symptoms. Eradication of H. pylori would slightly decrease this patient's chance of having persistent symptoms over the next three to 12 months.
Dyspepsia, often defined as chronic or recurrent discomfort centered in the upper abdomen, can be caused by a variety of conditions. Common etiologies include peptic ulcers and gastroesophageal reflux. Serious causes, such as gastric and pancreatic cancers, are rare but must also be considered. Symp...